Prelude Capital Management’s Immune Design Corp. IMDZ Stock Holding History

Prelude Capital Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-32,983	Closed	-$193K	–	2398
2019 Q1	$193K	Buy	+32,983	New	+$112K	0.01%	723
2018 Q3	–	Sell	-20,302	Closed	-$92K	–	2258
2018 Q2	$92K	Buy	+20,302	New	+$80.9K	0.01%	955
2017 Q3	–	Sell	-1,900	Closed	-$19K	–	2131
2017 Q2	$19K	Buy	1,900 +1,300	+217%	+$9.12K	﹤0.01%	1282
2017 Q1	$4K	Sell	600 -81	-12%	-$468	﹤0.01%	1432
2016 Q4	$4K	Buy	+681	New	+$4.81K	﹤0.01%	1469
2016 Q3	–	Sell	-800	Closed	-$7K	–	2057
2016 Q2	$7K	Buy	+800	New	+$9.98K	﹤0.01%	1439

Prelude Capital Management's IMDZ Position: Q2 2019 in Review

Prelude Capital Management sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 32,983 shares — an estimated $193K sold.

Prelude Capital Management first reported a position in IMDZ in Q2 2016 and held it in 6 quarters. The position peaked at $193K in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.

Prelude Capital Management reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
Prelude Capital Management sold 32,983 Immune Design Corp. shares in Q2 2019, an estimated $193K.
Prelude Capital Management first reported a position in Immune Design Corp. in Q2 2016 and held it in 6 quarters.
Prelude Capital Management's Immune Design Corp. position peaked at $193K in Q1 2019.
0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.